Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer

作者：Wang, Hua-qing; Ren, Yangang; Qian, Zheng-zi; Fu, Kai; Zhang, Hui-lai; Li, Wei; Hou, Yun; Zhou, Shi-yong; Hao, Xi-shan; Xie, Cong-hua^*

来源：Thoracic Cancer, 2012, 3(1): 72-78.

DOI：10.1111/j.1759-7714.2011.00083.x

• Advanced non-small-cell lung cancer
• combined therapy
• nimotuzumab
• second-line chemotherapy

Objective: To evaluate the efficacy and safety of nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) and to investigate the association of the status of KRAS gene mutation and epidermal growth factor receptor (EGFR) genotype with clinical outcome.

• 出版日期2012-2
• 单位中国医科大学; 武汉大学; 天津医科大学